Ind-Swift Laboratories Limited – NSE:INDSWFTLAB.NS

Ind-Swift Laboratories Limited stock price today

INR 74.7
-29.67
-28.43%
Financial Health
0
1
2
3
4
5
6
7
8
9

Ind-Swift Laboratories Limited stock price monthly change

-22.41%
month

Ind-Swift Laboratories Limited stock price quarterly change

-22.41%
quarter

Ind-Swift Laboratories Limited stock price yearly change

+3.49%
year

Ind-Swift Laboratories Limited key metrics

Market Cap
 6.39B
Enterprise value
 12.77B
P/E
 31.63
EV/Sales
 1.05
EV/EBITDA
 5.18
Price/Sales
 0.30
Price/Book
 0.57
PEG ratio
 1.00
EPS
 51.99
Revenue
 12.80B
EBITDA
 1.60B
Income
 3.07B
Revenue Q/Q
 29.28%
Revenue Y/Y
 6.09%
Profit margin
 0.93%
Oper. margin
 5.98%
Gross margin
 43.82%
EBIT margin
 5.98%
EBITDA margin
 12.53%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Ind-Swift Laboratories Limited stock price history

Ind-Swift Laboratories Limited stock forecast

Ind-Swift Laboratories Limited financial statements

Profit Margin

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB.NS): Profit margin
Jun 2023 3.10B 172.42M 5.56%
Sep 2023 2.89B 316.56M 10.93%
Dec 2023 2.87B 194.18M 6.75%
Mar 2024 3.93B 2.38B 60.72%
INDSWFTLAB.NS income statement history

Debt to Assets

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB.NS): Debt to assets
Jun 2023 0 0
Sep 2023 17992768000 10.68B 59.41%
Dec 2023 0 0
Mar 2024 11651063000 2.28B 19.65%
INDSWFTLAB.NS balance sheet history

Cash Flow

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB.NS): Cash Flow
Jun 2023 277.70M 0 0
Sep 2023 263.75M 0 0
Dec 2023 271.11M 0 0
Mar 2024 0 0 0
INDSWFTLAB.NS cash flow history

Ind-Swift Laboratories Limited alternative data

Ind-Swift Laboratories Limited
Employees

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB.NS): Employee count
Aug 2023 1,452
Sep 2023 1,452
Oct 2023 1,496
Nov 2023 1,496
Dec 2023 1,496
Jan 2024 1,496
Feb 2024 1,496
Mar 2024 1,496
Apr 2024 1,496
May 2024 1,496
Jun 2024 1,496
Jul 2024 1,496

Ind-Swift Laboratories Limited other data

Ind-Swift Laboratories Limited
Executives

Insider Compensation
Mr. Navarattan Munjal (1952) Chairman & MD
 $32,740,000
Mr. Himanshu Jain (1982) Joint MD & Whole Time Director
 $26,190,000
Mr. Sahil Munjal (1980) Pres of Operations & Special Assignments & Executive Director
 $14,910,000
Mr. Rishav Mehta (1991) Executive Director
 $13,100,000

Frequently Asked Questions (FAQ)

  • What's the price of Ind-Swift Laboratories Limited stock today?

    One share of Ind-Swift Laboratories Limited stock can currently be purchased for approximately $74.7.

  • When is Ind-Swift Laboratories Limited's next earnings date?

    Unfortunately, Ind-Swift Laboratories Limited's (INDSWFTLAB.NS) next earnings date is currently unknown.

  • Does Ind-Swift Laboratories Limited pay dividends?

    No, Ind-Swift Laboratories Limited does not pay dividends.

  • How much money does Ind-Swift Laboratories Limited make?

    Ind-Swift Laboratories Limited has a market capitalization of 6.39B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 23.31% to 12.81B US dollars.

  • What is Ind-Swift Laboratories Limited's stock symbol?

    Ind-Swift Laboratories Limited is traded on the NSE under the ticker symbol "INDSWFTLAB.NS".

  • What is Ind-Swift Laboratories Limited's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Ind-Swift Laboratories Limited?

    Shares of Ind-Swift Laboratories Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Ind-Swift Laboratories Limited's key executives?

    Ind-Swift Laboratories Limited's management team includes the following people:

    • Mr. Navarattan Munjal Chairman & MD(age: 73, pay: $32,740,000)
    • Mr. Himanshu Jain Joint MD & Whole Time Director(age: 43, pay: $26,190,000)
    • Mr. Sahil Munjal Pres of Operations & Special Assignments & Executive Director(age: 45, pay: $14,910,000)
    • Mr. Rishav Mehta Executive Director(age: 34, pay: $13,100,000)

  • How many employees does Ind-Swift Laboratories Limited have?

    As Jul 2024, Ind-Swift Laboratories Limited employs 1,496 workers.

  • When Ind-Swift Laboratories Limited went public?

    Ind-Swift Laboratories Limited is publicly traded company for more then 23 years since IPO on 1 Jul 2002.

  • What is Ind-Swift Laboratories Limited's official website?

    The official website for Ind-Swift Laboratories Limited is indswiftlabs.com.

  • How can i contact Ind-Swift Laboratories Limited?

    Ind-Swift Laboratories Limited can be reached via phone at +91 172 273 0503.

Ind-Swift Laboratories Limited company profile:

Ind-Swift Laboratories Limited

indswiftlabs.com
Exchange:

NSE

Full time employees:

47

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

+91 172 273 0503
Shivalik Enclave
Manimajra, 160101

:
ISIN: INE915B01019
CUSIP: Y3990X106